FOR IMMEDIATE RELEASE

 

Contact:

Glint Pharmaceuticals

617-957-9858

info@glintpharma.com

 

Allergy Drug Delivery Contact Lens Approved by Japan Regulatory Authority 

 

New Lens Aims to Treat Contact Lens Wearers Who Suffer from Seasonal Allergies 

 

SOMERVILLE, MA – March 31, 2021— Glint Pharmaceuticals reports that Johnsons & Jonson Vision Care has received regulatory approval for a new contact lens for the delivery anti-allergy medicine to the eye. The new lens is meant to be used by contact lenses wearers who suffer from seasonal allergies. The J&J lens is called Accuvue Theravision with Ketotifen and delivers the well know antihistamine medication Ketotifen. 

 

Glint Pharmaceuticals has also developed an anti-allergy contact lens that delivers medication over hours or days in a sustained controlled release process. The J&J lens is not based on controlled release. A controlled release process will deliver the medicine over an extended period and may have treatment benefits. 

 

The market for an anti-allergy lens is estimated to be over 50 million users in the US, Europe and Japan. Currently when contact lens wearers encounter seasonal allergy, they have limited options for controlling inflammation and itching. Most users resort to eye drop medications and temporarily stop wearing contact lenses. A lens that includes an anti-allergy medication will come as a relief to millions of contact lens users.

 

The patented controlled release Glint prototype lens is in the initial stages of development and the company expects to conduct safety clinical studies in the coming months. 

 

About Glint

Glint Pharmaceuticals, a Massachusetts company, is developing proprietary drug delivery technology for the treatment and prevention of ocular infections and diseases. Examples of diseases to be treated include eye infections and corneal abrasions, glaucoma, post-surgical ocular inflammation, allergic conjunctivitis, and dry eye. Over 40 million Americans suffer from ocular surface disease. The Glint technology has the potential to increase drug efficacy and improve patient compliance.

FOR IMMEDIATE RELEASE

 

Contact:

Glint Pharmaceuticals

617-957-9858

info@glintpharma.com

 

Glint Announces Formation of Clinical Advisory Board

 

Clinical Advisors to Guide Development of Glint Drug Delivery contact lens technology.

 

SOMERVILLE, MA – November 17, 2020 — Glint Pharmaceuticals announces the formation of a clinical advisory board composed of notable and experienced clinicians in ophthalmology and optometry. 

 

The clinicians on the advisory board include: Dr. Mark Abelson, Founder ORA, Inc., Dr. Cynthia Matossian, Medical Director, Matossian Eye Associates, an affiliate of Prism Vision Group, Dr. James Thimons, Medical Director, Ophthalmic Consultants of Connecticut, Dr. Mark Blecher, Professor Ophthalmology, Wills Eye Hospital and Dr. Paul Karpecki, Director, Kentucky Eye Institute, 

 

We are grateful to have such an experienced and knowledgeable group of clinicians join our advisory board to guide the development of our drug delivery technology to treat significant medical eye disease, says Chris Adams CEO. 

 

About Glint

Glint Pharmaceuticals, a Massachusetts company, is developing proprietary drug delivery technology for the treatment and prevention of ocular infections and diseases. Examples of diseases to be treated include, Covid-19 infection, glaucoma, ocular inflammation, conjunctivitis, allergic rhinitis, and dry eye. Over 40 million Americans suffer from ocular surface disease. The technology has the potential to increase drug efficacy and patient compliance.

FOR IMMEDIATE RELEASE

 

Contact:

Glint Pharmaceuticals

617-957-9858

info@glintpharma.com

 

Glint Announces Video Interview at 2020 INTERPHEX Conference

 

Interview highlights Glint Drug Delivery contact lens technology.

 

SOMERVILLE, MA – October 12, 2020 — Glint Pharmaceuticals announces the release of a video interview by the INTERPHEX 2020 conference. The interview includes a discussion with the Glint senior management team to highlight the company’s drug delivery contact lens technology and related market opportunities in glaucoma and infectious diseases.

 

The INTERPHEX conference is the premier pharmaceutical, biotechnology and device development and manufacturing event. INTERPHEX brings together over 10,000 global industry professionals and companies to exhibit, network and demonstrate leading edge products. The ability to transition to a virtual format this year has allowed the conference to reach a global audience. 

 

About Glint

Glint Pharmaceuticals, a Massachusetts company, is developing proprietary drug delivery technology for the treatment and prevention of ocular infections and diseases. Examples of diseases to be treated include, Covid-19 infection, glaucoma, ocular inflammation, conjunctivitis, allergic rhinitis, and dry eye. Over 40 million Americans suffer from ocular surface disease. The technology has the potential to increase drug efficacy and patient compliance.

 

----------------------------------------------------------------------------------------------------------------------------------

FOR IMMEDIATE RELEASE

 

Contact:

Glint Pharmaceuticals

617-531-8445

info@glintpharma.com

 

Glint Pharmaceuticals to Begin Clinical Testing on Contact Lens to Prevent COVID-19 Virus Infection

 

Patented Drug Delivery Technology Incorporates Formulation to Reduce Virus Transmission for the Contact Lens Customer. The patented new lens technology will reduce eye infection caused by Covid-19.

 

SOMERVILLE, MA – June 23, 2020 — Glint Pharmaceuticals has developed a patented drug delivery contact lens technology for delivery of an anti-COVID 19 formulation to the ocular surface to prevent and treat infection.

 

The proprietary formulation combines a well-tolerated ocular chemistry with the Glint drug delivery contact lens to kill a broad range of bacteria and viruses including COVID 19. The formulation has been demonstrated to effectively reduce virus infection in scientific and medical publications and has been reviewed for effectiveness by the FDA.

 

The prototype device is in the initial stages of development and Glint expects to conduct safety clinical studies in the coming months. Upon successful completion of the clinical studies the device will be available for consumer use in the 4th quarter of 2020 and will depend on FDA approval. Recent scientific publications have reported that one route of Covid 19 virus infection is through the eye. “Ocular delivery of an anti-viral and bacterial formulation to the eye surface will have a significant effect in reducing eye infections including Covid-19 transmission”, says Chris Adams, CEO of Glint Pharmaceuticals.

 

The patented drug delivery technology will deliver a measured amount of the anti-infection formulation during the day. Both the contact lens and anti-infection formation have been used extensively on humans without adverse reactions.

 

About Glint

Glint Pharmaceuticals, a Massachusetts company, is developing proprietary drug delivery technology for the treatment and prevention of ocular infections and diseases. Examples of diseases to be treated include, Covid-19 infection, glaucoma, ocular inflammation, conjunctivitis, allergic rhinitis, and dry eye. Over 40 million Americans suffer from ocular surface disease. The technology has the potential to increase drug efficacy and patient compliance. The Glint Pharmaceuticals anti-Covid-19 lens has not been cleared or approved by the FDA. More information can be found at, http://www.glintpharma.com.